Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Triple-hypertensive pharmaceutical composition

A composition and drug technology, applied in the field of pharmacy, can solve problems such as insignificant curative effect

Inactive Publication Date: 2017-01-11
SHENZHEN AUSA PHARM CO LTD +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When ACEI is used alone, there are certain deficiencies in clinical practice. First, its antihypertensive efficacy has a certain limit. According to literature reports, its total effective rate is only about 60%, and 40% are ineffective or have no significant curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Triple-hypertensive pharmaceutical composition
  • Triple-hypertensive pharmaceutical composition
  • Triple-hypertensive pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1: Preparation of Compound Amlodipine 5mg / Enalapril 10mg / Folic Acid 0.4mg

[0051] prescription:

[0052]

[0053] Preparation Process:

[0054] ⑴Take the prescribed amount of amlodipine, enalapril maleate, and folic acid, pass through a 100-mesh sieve, and mix them uniformly by the method of equal increments for later use;

[0055] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0056] (3) Mix the microcrystalline cellulose, starch and carboxymethyl starch sodium according to the prescription amount, and then mix them with the mixed raw material drugs in equal increments;

[0057] (4) Make soft materials with an appropriate amount of 5% povidone K-30, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-45°C;

[0058] (5) Add an appropriate amount of magnesium stearate to the dry granules, mix them evenly, and compress them into tablets after content determination.

Embodiment 2

[0059] Embodiment 2: Preparation of Compound Amlodipine 5mg / Benazepril 5mg / Folic Acid 0.4mg

[0060] prescription:

[0061]

[0062] Preparation Process:

[0063] (1) Take the prescribed amount of amlodipine, benazepril, and folic acid, pass through a 100-mesh sieve, and mix them evenly by the method of equal increments;

[0064] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0065] (3) Mix the microcrystalline cellulose, starch and carboxymethyl starch sodium according to the prescription amount, and then mix them with the mixed raw material drugs in equal increments;

[0066] (4) Make soft materials with an appropriate amount of 5% povidone K-30, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-45°C;

[0067] (5) Add an appropriate amount of magnesium stearate to the dry granules, mix them evenly, and compress them into tablets after content determination.

Embodiment 3

[0068] Example 3: Preparation of Compound Nicardipine 65mg / Perindopril 5mg / Folic Acid 0.8mg

[0069] prescription:

[0070]

[0071] Preparation Process:

[0072] (1) Take the nicardipine, perindopril, and folic acid of the prescribed amount, pass through a 100-mesh sieve, and mix them uniformly by the method of increasing in equal amounts for subsequent use;

[0073] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0074] (3) mix the microcrystalline cellulose, starch, carboxymethyl starch sodium according to the prescription amount and then mix with the mixed raw material drug in equal increments;

[0075] (4) Make soft material with an appropriate amount of 5% povidone K-30, granulate with 24 mesh sieve, granulate with 20 mesh sieve, and dry at 40-45°C;

[0076] (5) Add an appropriate amount of magnesium stearate to the dry granules, mix them evenly, and compress them into tablets after content determination.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a triple-hypertensive pharmaceutical composition. The triple-hypertensive pharmaceutical composition comprises the following components in therapeutically effective amount: 2mg-240mg of a calcium antagonist (CCB), 1.25mg-75mg of an angiotensin converting enzyme inhibitor (ACEI) and 0.4mg-1.6mg of folic acid compounds. The triple-hypertensive pharmaceutical composition has the advantages that the antihypertensive therapy effects of patients with 2-3-level hypertension can be effectively improved, the protection to target organs of the patients is enhanced, and the risk of complication of cerebral apoplexy caused by the hypertension is reduced; and besides, the triple-hypertensive pharmaceutical composition is easily taken by the patients, the treatment compliance is greatly improved, and the medical expense can be further lowered.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing calcium antagonist (CCB), angiotensin-converting enzyme inhibitor (ACEI) and folic acid, which is mainly used for treating grade 2 and grade 3 hypertension, preventing and delaying cerebral infarction caused by hypertension. stroke. The present invention belongs to the field of pharmacy. Background technique [0002] Essential hypertension is a major factor leading to coronary heart disease, stroke, congestive heart failure and kidney damage. At present, the prevalence of hypertension in my country has risen to 27.2%, and it is estimated that there are about 300 million patients. The main therapeutic goal of treating hypertensive patients is to minimize the overall risk of cardiovascular complications and death. Drugs to lower blood pressure can effectively reduce the morbidity and mortality of cardiovascular complications. [0003] Drugs currently used to lower blood pressure mainly i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/519A61K31/4422A61K31/55A61K38/05A61P9/12A61P9/10
CPCA61K31/4422A61K31/519A61K31/55A61K38/05A61K45/06A61K2300/00
Inventor 徐希平张磊刘平于多
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com